Literature DB >> 7311186

The usefulness and limitations of CEA assay in the management of colorectal cancer.

H Tomoda, M Furusawa.   

Abstract

We investigated the usefulness and limitations of the measurement of CEA in the evaluation of tumor resection and the detection of recurrence in colorectal cancer patients. Preoperatively, 46 of 90 patients (51.1%) had CEA values of 5.0 ng/ml or higher. The percentage of patients with elevated CEA in whom the CEA values returned to normal one month postoperatively was significantly higher in those who had undergone a curative resection than in those who had undergone a non-curative resection (p less than 0.02). Among patients with normal CEA values, the changes were nil or only slight in CEA values, one month postoperatively. Among 28 with recurrences, 24 (85.7%) had CEA values of 5.0 ng/ml or higher. All 11 with liver recurrences had values of 10.0 ng/ml or higher. In 4 with liver recurrences and in cases where CEA measurements were made, CEA values were found to be abnormal 3 to 10 months before the recurrences and a rapid elevation occurred for a short period. However, 4 out of 10 with local or lymphnode recurrences showed normal CEA values. CEA measurement was useful in detection of liver recurrences, but not so useful in detecting local or lymphnode recurrences.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7311186     DOI: 10.1007/bf02468817

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  18 in total

1.  Carcinoembryonic antigen in the diagnosis and management of colorectal carcinoma. Current status.

Authors:  A S Livingstone; L G Hampson; J Shuster; P Gold; E J Hinchey
Journal:  Arch Surg       Date:  1974-08

2.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.

Authors:  H J Wanebo; B Rao; C M Pinsky; R G Hoffman; M Stearns; M K Schwartz; H F Oettgen
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

3.  Detection of recurrence of large-bowel carcinoma by radioimmunoassay of circulating carcinoembryonic antigen (C.E.A.).

Authors:  J P Mach; P Jaeger; M M Bertholet; C H Ruegsegger; R M Loosli; J Pettavel
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

4.  Assessment of serial carcinoembryonic antigen (CEA) assays in postoperative detection of recurrent colorectal cancer.

Authors:  P H Sugarbaker; N Zamcheck; F D Moore
Journal:  Cancer       Date:  1976-12       Impact factor: 6.860

5.  CEA levels at recurrence and metastases; importance for detecting secondary disease.

Authors:  A Rieger; B Wahren
Journal:  Scand J Gastroenterol       Date:  1975       Impact factor: 2.423

6.  Carcinoembryonic antigen (CEA) as a prognostic and monitoring test in clinically complete resection of colorectal carcinoma.

Authors:  M A Herrera; T M Chu; E D Holyoke
Journal:  Ann Surg       Date:  1976-01       Impact factor: 12.969

7.  Carcinoembryonic antigen (CEA) in inflammatory bowel disease.

Authors:  T L Moore; P A Kantrowitz; N Zamcheck
Journal:  JAMA       Date:  1972-11-20       Impact factor: 56.272

8.  Use of CEA as an indicator of early recurrence and as a guide to a selected second-look procedure in patients with colorectal cancer.

Authors:  J H Wanebo; M Stearns; M K Schwartz
Journal:  Ann Surg       Date:  1978-10       Impact factor: 12.969

9.  The use of CEA as an early indicator for gastrointestinal tumor recurrence and second-look procedures.

Authors:  E W Martin; K K James; P E Hurtubise; P Catalano; J P Minton
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

10.  Carcinoembryonic antigen (CEA) assays in obstructive colorectal cancer.

Authors:  P H Sugarbaker
Journal:  Ann Surg       Date:  1976-12       Impact factor: 12.969

View more
  2 in total

1.  Carcinoembryonic antigen and recurrent colorectal cancer.

Authors:  J Northover
Journal:  Gut       Date:  1986-02       Impact factor: 23.059

Review 2.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.